Skip to main content

Table 4 Effectiveness, costs, transition probabilities, base case discount rate and variations in sensitivity analysis

From: Cost-effectiveness analysis of XELOX versus XELOX plus bevacizumab for metastatic colorectal cancer in a public hospital school

Parameters

Base case

Variation in sensitivity analysis

Reference

Overall survival of first-line therapy (strategy 1)

17.6

15.8–19.3

Macedo et al. (2012) [7]

Overall survival of second-line therapy (strategy 1)

20.6

18.5–22.6

Tournigand et al. (2004) [12]

Overall survival of supportive care (strategy 1)

18

16.2–19.8

Van Cutsem et al. (2007) [18]

Overall survival of first-line therapy (strategy 2)

19.8

17.8–21.8

Macedo et al. (2012) [7]

Overall survival of second-line therapy (strategy 2)

20.6

18.5–22.6

Tournigand et al. (2004) [12]

Overall survival of supportive care (strategy 2)

18

16.2–19.8

Van Cutsem et al. (2007) [18]

Cost of first-line therapy (strategy 1)

8256.32

6636.06–9876.58

Assumed

Cost of second-line therapy (strategy 1)

12,984.00

11,600.7–14,367.3

Assumed

Cost of supportive care (strategy1)

5032.51

4529.26–5535.76

Assumed

Cost of first-line therapy (strategy 2)

30,805.48

20,664–40,946.96

Assumed

Cost of second-line therapy (strategy 2)

12,984.00

11,600.7–14,367.3

Assumed

Cost of supportive care (strategy2)

5032.51

4529.26–5535.76

Assumed

Probability of transition from first-line therapy to first-line therapy (strategy 1)

0.66

0.60–0.72

Assumed

Probability of transition from first-line therapy to second-line therapy (strategy 1)

0.2

0.18–0.22

Hurwitz et al.

(2013) [17]

Probability of transition from first-line therapy to supportive care (strategy 1)

0.08

0.07–0.09

Saltz et al. (2008) [4]

Probability of transition from first-line therapy to death (strategy 1)

0.06

0.04–0.08

Hurwitz et al. (2013) [17]

Probability of transition from second-line therapy to second-line therapy (strategy 1)

0.49

0.45–0.53

Tournigand et al. (2004) [12]

Probability of transition from second-line therapy to supportive care (strategy 1)

0.45

0.41–0.49

Tournigand et al. (2004) [12]

Probability of transition from second-line therapy to death (strategy 1)

0.06

0.04–0.08

Tournigand et al. (2004) [12]

Probability of transition from supportive care to supportive care (strategy 1)

0.75

0.68–0.82

Van Cutsem et al. (2007) [18]

Probability of transition from supportive care to death (strategy 1)

0.25

0.23–0.27

Van Cutsem et al. (2007) [18]

Probability of transition from first-line therapy to first-line therapy (strategy 1)

0.67

0.61–0.73

Assumido

Probability of transition from first-line therapy to second-line therapy (strategy 1)

0.12

0.10–0.14

Hurwitz et al. (2013) [17]

Probability of transition from first-line therapy to supportive care (strategy 1)

0.16

0.14–0.18

Saltz et al. (2008) [4]

Probability of transition from first-line therapy to death (strategy 1)

0.05

0.04–0.06

Hurwitz et al. (2013) [17]

Probability of transition from second-line therapy to second-line therapy (strategy 1)

0.49

0.45–0.53

Tournigand et al. (2004) [12]

Probability of transition from second-line therapy to supportive care (strategy 1)

0.45

0.41–0.49

Tournigand et al. (2004) [12]

Probability of transition from second-line therapy to death (strategy 1)

0.06

0.04–0.08

Tournigand et al. (2004) [12]

Probability of transition from supportive care to supportive care (strategy 1)

0.75

0.68–0.82

Van Cutsem et al. (2007) [18]

Probability of transition from supportive care to death (strategy 1)

0.25

0.23–0.27

Van Cutsem et al. (2007) [18]

Discount rate

5%

0–10%

Brasil, 2014 [13]